CT-1 是一种属于 IL-6 细胞因子家族的分泌蛋白,其过表达可通过 ADMA/DDAH 通路增强细胞增殖、迁移及血管形成能力,并通过同时诱导 N2 型肿瘤相关中性粒细胞与癌细胞发生铁死亡 (Ferroptosis) 抑制三阴性乳腺癌细胞的生长,还可激活 Jak/STAT-3、p42/p44 MAPK 和 AMPK 通路,通过磷酸化作用抑制 GSK-3β 活性并诱导心肌细胞肥大,增强心肌细胞和神经元的存活能力、减少细胞凋亡 (Apoptosis)、诱导热休克蛋白 (HSP) 和 BNP 的表达并抑制 TNF 水平,从而在三阴性乳腺癌小鼠模型中发挥抗肿瘤活性并改善小鼠认知功能障碍,因此可用于缺血性心脏病、三阴性乳腺癌、心肌肥大、帕金森病、高血压性心脏病、心肌梗死、急性恰加斯心肌病、高脂饮食诱导的认知障碍及糖尿病相关认知障碍的研究。
CT-1
产品编号: MS-V70265 纯度: 99.90% 分子式: C23H22O6 分子量: 394.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

CT-1 是一种属于 IL-6 细胞因子家族的分泌蛋白,其过表达可通过 ADMA/DDAH 通路增强细胞增殖、迁移及血管形成能力,并通过同时诱导 N2 型肿瘤相关中性粒细胞与癌细胞发生铁死亡 (Ferroptosis) 抑制三阴性乳腺癌细胞的生长,还可激活 Jak/STAT-3、p42/p44 MAPK 和 AMPK 通路,通过磷酸化作用抑制 GSK-3β 活性并诱导心肌细胞肥大,增强心肌细胞和神经元的存活能力、减少细胞凋亡 (Apoptosis)、诱导热休克蛋白 (HSP) 和 BNP 的表达并抑制 TNF 水平,从而在三阴性乳腺癌小鼠模型中发挥抗肿瘤活性并改善小鼠认知功能障碍,因此可用于缺血性心脏病、三阴性乳腺癌、心肌肥大、帕金森病、高血压性心脏病、心肌梗死、急性恰加斯心肌病、高脂饮食诱导的认知障碍及糖尿病相关认知障碍的研究。

生物实验数据

生物活性 CT-1 is a secreted protein belonging to the IL-6 cytokine family that, upon overexpression, enhances cell proliferation, migration, and angiogenesis through the ADMA/DDAH pathway, inhibits the growth of triple-negative breast cancer cells by simultaneously inducing ferroptosis in N2-type tumor-associated neutrophils and cancer cells, activates the Jak/STAT-3, p42/p44 MAPK, and AMPK pathways, inhibits GSK-3β activity through phosphorylation, and induces cardiomyocyte hypertrophy, while also enhancing the survival of cardiomyocytes and neurons, reducing apoptosis, inducing the expression of heat shock proteins (HSP) and BNP, and suppressing TNF levels, thereby exerting antitumor activity in mouse models of triple-negative breast cancer and improving cognitive dysfunction in mice, and is therefore applicable to research on ischemic heart disease, triple-negative breast cancer, cardiac hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment, and diabetes-related cognitive impairment.
体外研究
(In Vitro)

CT-1 (转染后 48 h) 过表达可显著促进 HUVECs 的增殖、迁移,增强细胞毛细血管管形成能力,显著上调 eNOS mRNA 的表达,上调 DDAH I、DDAH II 和 VEGF 的蛋白表达水平。
CT-1 (转染后 48 h) 过表达可显著降低 HUVECs 中 ADMA 的水平,并提高其 DDAH 活性,提升 NOS 活性及 NO 生成量。
CT-1 (0.78-12.5 μM; 0-300s) 可结合纯化的人源 FTH1、野生型 FTH1,Kd 分别为 17.15、5.46 μM。
CT-1 (100 μM;1 h) 与 4T1 细胞裂解物中的 FTH1 相互作用,降低 FTH1 对链霉蛋白酶介导的蛋白水解作用的稳定性。
CT-1 (0.5-16 μM; 24 h) 可抑制 4T1、MDA-MB-231、N2 型肿瘤相关中性粒细胞 (经极化的 HL-60 细胞) 细胞的活力。
CT-1 (24 h) 可抑制原代小鼠 N2 样中性粒细胞的活力, IC50 为 7.16 μM。
CT-1 (0-8 μM; 24 h) 升高 4T1 细胞内的 Fe2+ 水平、GSSG/GSH 比值 (氧化应激的标志物),降低细胞的线粒体膜电位,促进细胞内的 ROS 生成,诱导细胞发生脂质过氧化,促进细胞中 FTH1 的溶酶体自噬降解。
CT-1 (1-4 μM; 24 h) 诱导 N2 型肿瘤相关中性粒细胞 (经极化的 HL-60 细胞) 发生脂质过氧化。
CT-1 (0.25-32 μM; 6 days) 以剂量依赖的方式抑制三阴性乳腺癌类器官的生长与活性,处理 6 天后,在 3 株 PDO 细胞系中的 IC50 值为 2.35 至 6.74 μM。
CT-1 (0.1 nM or lower) 可强效诱导新生心肌细胞产生类似容量过载的肥大,可通过减少细胞凋亡提高无血清培养基中新生大鼠心肌细胞的存活率,诱导培养的心肌细胞中 ANP、BNP、hsp70 及 hsp90 基因的表达。
CT-1 (30 min) 可保护体外培养的新生心肌细胞免受模拟缺氧/缺血应激诱导的细胞死亡与凋亡,该效应依赖于 p42/p44 MAPK 通路的激活 (可被 50 μM PD98059 (MS-N60869) 抑制)。

Cell Viability Assay

Cell Line: 4T1、MDA-MB-231 cells、N2-type TANs (polarized HL-60 cells)
Concentration: 0.5, 1, 2, 4, 8, 16, 32 μM
Incubation Time: 24 h
Result: Inhibited 4T1 cell viability in a dose-dependent manner.
Inhibited MDA-MB-231 cell viability in a dose-dependent manner.
Inhibited N2-type TAN viability in a dose-dependent manner, with greater sensitivity observed compared to N1-type TANs.

Western Blot Analysis

Cell Line: 4T1 murine TNBC cells
Concentration: 4 μM; 5 μM MG132, 100 nM BafA1, or 10 μM CQ (co-treatment)
Incubation Time: 24 h
Result: Induced FTH1 protein degradation.
Showed no reversal of this degradation by MG132 (proteasome inhibitor), while BafA1 and CQ (lysosomal inhibitors) significantly inhibited CT-1-mediated FTH1 degradation.
体内研究
(In Vivo)

CT-1 (5-10 mg/kg,i.v.,每日 1 次,连续 14 天) 可在 EMT6 三阴性乳腺癌小鼠模型中诱导铁死亡,显著降低肿瘤重量,上调氧化应激和脂质过氧化标志物水平,同时下调铁死亡抑制蛋白 FTH1 和 GPX4 的表达,在中性粒细胞被耗竭的情况下,对原位 4T1 三阴性乳腺癌肿瘤的抗肿瘤效力降低。
CT-1 (1 μg/天;i.c.v.;每日给药;连续 14 天) 可通过逆转代谢功能障碍、减轻神经炎症、增强海马体胰岛素/IGF 信号通路以及恢复突触蛋白水平,改善高脂饮食诱导的雄性 C57BL/6 小鼠认知损伤,可通过激活 AMPK 改善 ICV-Streptozotocin (STZ) (MS-Q80520) 处理小鼠的认知障碍、线粒体功能异常、突触丢失及胰岛素信号通路缺陷。

Animal Model: BALB/c (female, 4 weeks old, orthotopic EMT6 tumor model/orthotopic 4T1 tumor model/orthotopic 4T1 tumor model with neutrophil depletion and N2-type neutrophil adoptive transfer)
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.v.; daily; 14 days
Result: Significantly reduced tumor weights.
Elevated ROS (DHE-positive staining) and lipid peroxidation (4-HNE-positive staining,).
Reduced FTH1 and GPX4 expression.
Extended mouse survival at 10 mg/kg.
Reduced neutrophils (CD11b+ Ly6G+), reduced pro-tumor N2-type TANs (CD206+), and increased anti-tumor N1-type TANs (NOS2+) in tumor immune microenvironments.
Maintained stable body weight, indicating no overt toxicity.
Diminished anti-tumor efficacy compared to non-depleted mice treated with CT-1.
Showed significantly less pronounced tumor volume and weight reduction.
Animal Model: C57BL/6 (4-week-old male; high-fat diet-induced cognitive impairment model)/(6-month-old, either sex, bilateral ICV injections of STZ on day 1 and day 3)
Dosage: 1 μg/day
Administration: intracerebroventricular (i.c.v.) injection; daily; 14 consecutive days
Result: Increased novel object recognition index by 45.4%.
Significantly decreased Morris water maze escape latencies from training day 3 onward, increased time spent in the target quadrant by 54.5%, and increased crossing-target number by 57.1%.
Reduced body weight gain in HFD-fed mice, and restored near-normal levels of blood insulin, glucose, free fatty acids, and cholesterol.
Reduced hippocampal proinflammatory cytokines TNF-α by 41.4% and IL-1β by 31.7%, and increased anti-inflammatory cytokine IL-10 by 47.7%.
Increased hippocampal IRS-1 expression by 33.3%, reduced IRS-1 phosphorylation by 46.1%, increased Akt phosphorylation by 1.10-fold, and increased GSK-3β phosphorylation by 71.1%.
Increased hippocampal levels of postsynaptic protein PSD95 by 44.4% and dendritic spine-specific protein drebrin by 48.9%.
Significantly reduced escape latency in the Morris water maze hidden platform task compared to STZ-treated mice.
Increased crossing-target number in the probe test by 71.4% compared to STZ-treated mice.
Significantly improved mitochondrial function in STZ-treated mice, as shown by increased cytochrome oxidase (COX) activity, increased ATP levels, decreased reactive oxygen species (ROS) production, and increased mitochondrial membrane potential (MMP).
Significantly increased synaptic density in the hippocampal CA1 region of STZ-treated mice.
Restored impaired hippocampal insulin signaling in STZ-treated mice, increasing expression levels of IRS-1, p-Akt, p-GSK-3β, and p-AMPK, and reducing expression levels of p-IRS-1.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 394.42
分子式 C23H22O6

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (126.77 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.5354 mL12.6768 mL25.3537 mL63.3842 mL
5 mM0.5071 mL2.5354 mL5.0707 mL12.6768 mL
10 mM0.2535 mL1.2677 mL2.5354 mL6.3384 mL
15 mM0.1690 mL0.8451 mL1.6902 mL4.2256 mL
20 mM0.1268 mL0.6338 mL1.2677 mL3.1692 mL
25 mM0.1014 mL0.5071 mL1.0141 mL2.5354 mL
30 mM0.0845 mL0.4226 mL0.8451 mL2.1128 mL
40 mM0.0634 mL0.3169 mL0.6338 mL1.5846 mL
50 mM0.0507 mL0.2535 mL0.5071 mL1.2677 mL
60 mM0.0423 mL0.2113 mL0.4226 mL1.0564 mL
80 mM0.0317 mL0.1585 mL0.3169 mL0.7923 mL
100 mM0.0254 mL0.1268 mL0.2535 mL0.6338 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础